Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kesuting Syrup for Light COVID-19
NCT05366231Phase 4Completed
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
A Phase 4 trial of kesuting in coronavirus disease 2019 (COVID-19), sponsored by Guizhou Bailing Group Pharmaceutical Co., Ltd.. Started May 2022; status: completed.
02
Drugs
kesuting
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05366231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366231.